Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain
Year: 2019
Type: article
Abstract: Background Cannabidiol (CBD) is a natural compound of cannabis, which exerts complex and widespread immunomodulatory, antioxidant, anxiolytic, and antiepileptic properties. Many experimental data suggest that CBD could have several types of application in alcohol use disorder (AUD) and alcohol-related damage on the brain and the liver. Aim To provide a rationale for using CBD in human subjects with AUD, based on the findings of the experimental studies. Methods Narrative review of the studies pertaining to the assessment of CBD for reducing drinking, or improving any aspect of alcohol-related toxicity in AUD. Results Experimental studies converge to find that CBD reduces the overall level of alcohol drinking in animal models of AUD by reducing ethanol intake, motivation for ethanol, relapse, and by decreasing anxiety and impulsivity. Moreover, CBD has been shown to reduce alcohol-related steatosis and fibrosis in the liver by reducing lipid accumulation, stimulating autophagy, modulating inflammation, reducing oxidative stress, and inducing death of activated hepatic stellate cells. Last, CBD has been found to reduce alcohol-related brain damage, preventing neuronal loss by its antioxidant and immunomodulatory properties. Conclusions CBD could directly reduce alcohol drinking in subjects with AUD. But other original applications warrant human trials in this population. By reducing alcohol-related processes of steatosis in the liver, and brain alcohol-related damage, CBD could improve both the hepatic and neurocognitive outcomes of subjects with AUD, regardless of the individual drinking trajectories. This might pave the way for testing new harm reduction approaches in AUD, i.e., for protecting the organs of subjects with an ongoing AUD.
Source: Frontiers in Pharmacology
Institutions: Centre Hospitalier Le Vinatier, Inserm, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Université de Picardie Jules Verne, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille Inflammation Research International Center, Hôpital Claude Huriez, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon 1 Université, Centre National de la Recherche Scientifique, Université de Lyon, Centre de Recherche en Neurosciences de Lyon, UCLouvain, KU Leuven, Sciences Cognitives et Sciences Affectives, Aix-Marseille Université, Economic & Social Sciences, Health Systems & Medical Informatics, Institut de Recherche pour le Développement
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,950
OpenAlex ID: W2944995071